RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2021 -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and Gilbert...
Emil Kakkis harvesting academic sources for Orphan drug newco Ultragenyx
News | 12. 19. 2011
Ultragenyx Pharmaceutical
Emil Kakkis harvesting academic sources for Orphan drug newco Ultragenyx
By Jennifer Rhodes
Staff Writer
Published on Monday, December 19, 2011
Ultragenyx Pharmaceutical Inc. is taking a traditional approach to Orphan Drugs by in-licensing development-ready substrate and enzyme replacement therapies that have a clear mechanistic rationale and proof of concept in animals for rare and ultra-rare genetic diseases.
Founder, President and CEO Emil Kakkis believes there are a few hundred such diseases with no current treatments.
